SCHEMBL2807309

SCHEMBL2807309

COC(=O)CCCCC(=O)c1c(C)n(CC(O)COc2ccc(-c3ccccc3)cc2)c2ccc(C(=O)O)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 2/20 0.43
PTGER4 P35408 2/20 0.42
MAPT P10636 5/20 0.41
LMNA P02545 4/20 0.41
NPSR1 Q6W5P4 3/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RECQL P46063 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPK1 P28482 3/20 0.41
TSHR P16473 2/20 0.41
USP2 O75604 1/20 0.41
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2806883 0.93 PLA2G2A (0.43) PLA2G2AMAPTLMNANPSR1KDM4E
SCHEMBL3653407 0.90 PTGER4 (0.41) PLA2G2APTGER4MAPTLMNANPSR1
SCHEMBL2804338 0.87 PLA2G4A (0.50) PLA2G2APLA2G4A
SCHEMBL2807126 0.85 PLA2G4A (0.50) PLA2G2APLA2G4A
SCHEMBL2808268 0.85 PLA2G4A (0.45) PLA2G2ATSHRALDH1A1PLA2G4A
SCHEMBL2809729 0.78 PLA2G4A (0.50) PLA2G2APLA2G4A
SCHEMBL2807308 0.77 MAPT (0.44) MAPTLMNAMAPK1USP2SMN1; SMN2
SCHEMBL2805614 0.73 PLA2G2A (0.41) PLA2G2APTGER4MAPTKDM4ETSHR
SCHEMBL2806320 0.73 PLA2G4A (0.52) MAPTTP53PLA2G4A
SCHEMBL2806144 0.72 PLA2G4A (0.64) PLA2G4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100240718-A1 NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 WESTFALISCHE WILHELMS UNIVERSITÄT MÜNSTER (DE) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240718-A1 NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 PLD2, PLA2G1B, PLA2G4A PLA2G2A 9/4885PTGER4 874/4885MAPT 4523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.